AMANTA vs VIVOBIOT: Stock Comparison
AMANTA shows faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AMANTA leads 3; VIVOBIOT leads 3 of 7
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AMANTA | VIVOBIOT |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | AMANTA | VIVOBIOT |
|---|---|---|
| Live Price | ₹150.27 | ₹17 |
| Day Change | -4.37% | 1.01% |
| Volume | 3.82 L | 3,282 |
| 52-Week High | ₹164 | ₹20.94 |
| 52-Week Low | ₹92 | ₹16 |
| Distance from 52W High | -8.37% | -18.82% |
Valuation
| Metric | AMANTA | VIVOBIOT |
|---|---|---|
| Market Cap | ₹749 Cr | ₹0 Cr |
| P/E Ratio | 53.58x | — |
| P/B Ratio | 3.57x | — |
| EPS | ₹0.85 | ₹0.08 |
| Book Value | ₹56.71 | ₹41.98 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | AMANTA | VIVOBIOT |
|---|---|---|
| Revenue Growth (TTM YoY) | 6.8% | 0% |
| EPS Growth (TTM YoY) | -23.4% | 0% |
| Qtr Sales Growth | -76.08% | 0.99% |
| Qtr Profit Growth | -77.74% | 1.79% |
Profitability & Leverage
| Metric | AMANTA | VIVOBIOT |
|---|---|---|
| ROE | 6.75% | — |
| ROCE | 7.89% | — |
| Net Margin | 5.17% | 0% |
| Operating Margin | 14.55% | — |
| Debt to Equity | 1.06x | — |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AMANTA | VIVOBIOT |
|---|---|---|
| Promoter Holding | 26.87%▲ 0.06 pp | 30.62%▼ 4.81 pp |
| FII Holding | 0.43%▼ 0.42 pp | 0% |
| DII Holding | 12.92%▲ 0.04 pp | 0% |
| Public Holding | 22.85%▲ 0.29 pp | 69.38%▲ 4.81 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AMANTA and VIVO BIO TECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.